Interventional Ablation for Early-stage Lung Cancer

Summary

What is this study about? This clinical trial aims to compare two treatments for high-risk lung nodules or early-stage lung cancer: interventional ablation (a minimally invasive procedure that destroys tumors with heat or cold) and surgical resection (surgery to remove the tumor). The goal is to determine if ablation is as safe and effective as surgery while preserving more lung function.

Why is this important? Lung cancer is a leading cause of cancer deaths worldwide. Early detection improves survival, but surgery can damage lung function.

Ablation (e.g., microwave, cryotherapy) is less invasive than surgery and may offer similar outcomes with faster recovery. However, more evidence is needed to confirm its role in early-stage disease.

Conditions

• Lung Cancer (NSCLC)
• Early Stage Lung Non-Small Cell Carcinoma

Sponsors & Collaborators

• Hunan Provincial People's Hospital

  collaborator OTHER

• Beijing Chao Yang Hospital

  collaborator OTHER

• Fuda Cancer Hospital, Guangzhou

  collaborator OTHER

• University of South China Affiliated Nanhua Hospital

  collaborator UNKNOWN

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• The First Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Eastern Theater General Hospital,QinHuai District Medical Area

  collaborator UNKNOWN

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  collaborator OTHER

• Emergency General Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• The Second Hospital of Anhui Medical University

  collaborator OTHER

• Huaxi Hospital

  collaborator OTHER

• Shanghai Chest Hospital

  collaborator OTHER

• Military 301 Hospital

  collaborator UNKNOWN

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Guangzhou Institute of Respiratory Disease

  lead OTHER

Principal Investigators

• Chengzhi Zhou, Doctor · Guangzhou Institute of Respiratory Disease (Responsible Party)

Eligibility

Min Age

20 Years

Max Age

79 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-04-12

Primary Completion

2028-12-21

Completion

2028-12-31

Countries

• China

Study Locations